First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic ...

BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...